Inside PBMs' tactics to tilt the market; Is the KRAS race still on? CAR-T safety scares trigger halts; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
We are, thankfully, headed into a three-day weekend here at Endpoints News. For those of you who follow the daily reports, see you on Tuesday. Otherwise, enjoy the rest and this report will hit your inbox again next Saturday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.